Financhill
Sell
23

MRK Quote, Financials, Valuation and Earnings

Last price:
$95.69
Seasonality move :
1.28%
Day range:
$95.76 - $98.27
52-week range:
$94.48 - $134.63
Dividend yield:
3.24%
P/E ratio:
20.18x
P/S ratio:
3.87x
P/B ratio:
5.47x
Volume:
17.6M
Avg. volume:
11.1M
1-year change:
-19.05%
Market cap:
$243.5B
Revenue:
$60.1B
EPS (TTM):
$4.77

Analysts' Opinion

  • Consensus Rating
    Merck & has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $125.13, Merck & has an estimated upside of 30.02% from its current price of $96.24.
  • Price Target Downside
    According to analysts, the lowest downside price target is $100.00 representing -3.91% downside risk from its current price of $96.24.

Fair Value

  • According to the consensus of 21 analysts, Merck & has 30.02% upside to fair value with a price target of $125.13 per share.

MRK vs. S&P 500

  • Over the past 5 trading days, Merck & has underperformed the S&P 500 by -6.46% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Merck & does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Merck & has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Merck & reported revenues of $16.7B.

Earnings Growth

  • Merck & earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Merck & reported earnings per share of $1.24.
Enterprise value:
267B
EV / Invested capital:
--
Price / LTM sales:
3.87x
EV / EBIT:
17.84x
EV / Revenue:
4.23x
PEG ratio (5yr expected):
0.12x
EV / Free cash flow:
18.00x
Price / Operating cash flow:
16.49x
Enterprise value / EBITDA:
13.88x
Gross Profit (TTM):
$47.9B
Return On Assets:
11.06%
Net Income Margin (TTM):
19.23%
Return On Equity:
29.26%
Return On Invested Capital:
15.67%
Operating Margin:
23.92%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $59B $59.3B $63.2B $16B $16.7B
Gross Profit $41.6B $43.2B $47.9B $11.7B $12.6B
Operating Income $18.5B $8.2B $14.2B $5.9B $4B
EBITDA $21.6B $12.3B $19.2B $7B $5.6B
Diluted EPS $6.01 $1.80 $4.77 $1.86 $1.24
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $26.6B $31.1B $33.6B $32B $40.4B
Total Assets $89.8B $93.5B $107.1B $106.7B $117.5B
Current Liabilities $20.4B $23.7B $23B $23.1B $29.6B
Total Liabilities $60.5B $57.6B $62.6B $65.4B $73B
Total Equity $29.3B $35.9B $44.5B $41.3B $44.6B
Total Debt $28.7B $26.4B $30.4B $34.9B $38.1B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $19.7B $17.2B $18.3B $7.7B $9.3B
Cash From Investing -$15.3B -$15.9B -$6.2B -$334M -$3.8B
Cash From Financing -$2.4B -$4.1B -$6.3B -$4.3B -$2.4B
Free Cash Flow $15.2B $13.2B $14.8B $6.8B $8.5B
MRK
Sector
Market Cap
$243.5B
$45.7M
Price % of 52-Week High
71.49%
47.48%
Dividend Yield
3.24%
0%
Shareholder Yield
3.05%
-0.75%
1-Year Price Total Return
-19.05%
-32.34%
Beta (5-Year)
0.390
0.746
Dividend yield:
3.24%
Annualized payout:
$2.96
Payout ratio:
63.72%
Growth streak:
13 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $99.34
200-day SMA
Sell
Level $115.70
Bollinger Bands (100)
Sell
Level 98.79 - 112.97
Chaikin Money Flow
Buy
Level 728.9M
20-day SMA
Sell
Level $99.38
Relative Strength Index (RSI14)
Sell
Level 37.76
ADX Line
Sell
Level 22.55
Williams %R
Buy
Level -93.3426
50-day SMA
Sell
Level $99.97
MACD (12, 26)
Sell
Level -0.58
25-day Aroon Oscillator
Sell
Level -96
On Balance Volume
Neutral
Level 773.5M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (3.8362)
Sell
CA Score (Annual)
Level (-0.6378)
Buy
Beneish M-Score (Annual)
Level (-3.0002)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (19.6764)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Stock Forecast FAQ

In the current month, MRK has received 14 Buy ratings 7 Hold ratings, and 0 Sell ratings. The MRK average analyst price target in the past 3 months is $125.13.

  • Where Will Merck & Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Merck & share price will rise to $125.13 per share over the next 12 months.

  • What Do Analysts Say About Merck &?

    Analysts are divided on their view about Merck & share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Merck & is a Sell and believe this share price will drop from its current level to $100.00.

  • What Is Merck &'s Price Target?

    The price target for Merck & over the next 1-year time period is forecast to be $125.13 according to 21 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.

  • Is MRK A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Merck & is a Buy. 14 of 21 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of MRK?

    You can purchase shares of Merck & via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Merck & shares.

  • What Is The Merck & Share Price Today?

    Merck & was last trading at $95.69 per share. This represents the most recent stock quote for Merck &. Yesterday, Merck & closed at $96.24 per share.

  • How To Buy Merck & Stock Online?

    In order to purchase Merck & stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Philip Morris Stock Overvalued?
Is Philip Morris Stock Overvalued?

If there is one industry that can be termed truly…

What Quantum Stocks Should I Buy?
What Quantum Stocks Should I Buy?

The last several years have seen a series of tech…

Will Sirius XM Be a 10-Bagger Stock?
Will Sirius XM Be a 10-Bagger Stock?

Last year, Warren Buffett surprised practically everyone when he acquired…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
32
FTAI alert for Jan 22

FTAI Aviation [FTAI] is up 9.81% over the past day.

Sell
2
EDU alert for Jan 22

New Oriental Education & Technology Group [EDU] is down 1.13% over the past day.

Buy
51
GH alert for Jan 22

Guardant Health [GH] is up 4.5% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock